Human GPRC5D Full Length Protein (VLP)

AIDD‑Ready
Related Products: Cell line CHEK-STP042
1/5
+2 View all
Numéro de produit/spécification
Prix
Availability
Qté
GPD-H52P7-20ug
$620.00
In Stock - Delivery in 1-2 business days
GPD-H52P7-100ug
$1,235.00
In Stock - Delivery in 1-2 business days
GPD-H52P7-500ug
$4,305.00
In Stock - Delivery in 1-2 business days
GPD-H52P7
Montant du produit :
$ 0
0
Ajouter au panier
Suggestion de nouveau produit Request Quote
Contact Us
Contact Us
Montant du produit:
$ 0
0
Ajouter au panier
  • Détails du produit
  • Affichage des données
  • Reviews & Citations
  • Important Statement
  • Resources
Application
  • Immunization
  • Cell based assay (FACS or functional assay)
  • Screening (ELISA)
Synonyms

GPRC5D, G-protein coupled receptor family C group 5 member D

Source

Human GPRC5D Full Length Protein (VLP) (GPD-H52P7) is expressed from human 293 cells (HEK293). It contains AA Tyr 2 - Val 345 (Accession # Q9NZD1-1).

Predicted N-terminus: Asp

Molecular Characterization

*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

Structure

Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

Synthesis Process

Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SEC-HPLC.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.

Introduction de fond

An orphan G protein-coupled receptor with highly restricted expression in malignant plasma cells and hard keratinized tissues (hair/nail). This profile mitigates off-tumor toxicity, establishing GPRC5D as a breakthrough target for bispecific antibodies and CAR-T therapies in relapsed/refractory multiple myeloma.